Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified at the N-terminus to resist enzymatic degradation. AminoOptimization Group supplies it as a lyophilised research powder in 5 mg and 10 mg presentations, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is TESAMORELIN?
Tesamorelin corresponds to the full 44-residue sequence of human GRF (growth hormone-releasing factor), GRF(1-44)-NH2, rather than to the truncated 29-residue fragment used in several other synthetic GHRH analogues. Retaining the complete native sequence means the entire receptor-binding domain identified in the literature is present, not only the minimum fragment shown to retain activity.
The distinguishing feature of tesamorelin is a trans-3-hexenoic acid group acylated onto the N-terminal tyrosine residue. Native GHRH is inactivated primarily by dipeptidyl peptidase-4 (DPP-4), which cleaves the Tyr-Ala bond at the peptide’s N-terminus. Published structural work describes the hexenoyl modification as sterically hindering that cleavage, which is reported to extend the compound’s circulating half-life relative to unmodified GRF(1-44) without introducing an albumin-binding moiety of the kind used in some DAC-conjugated analogues.
As a full-length, DPP-4-resistant GHRH analogue, tesamorelin is classified in the literature as a growth hormone-releasing hormone receptor agonist. This places it in the same broad mechanistic family as truncated fragments such as Modified GRF (1-29), while remaining structurally and pharmacokinetically distinct from them.
Specifications
- Compound: Tesamorelin
- CAS number: 218949-48-5
- Molecular formula: C221H366N72O67S
- Molecular weight: 5135.86 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 5 mg, 10 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
GHRH analogues are studied for what they reveal about regulation of the somatotropic axis at the level of the anterior pituitary. Published research examines GHRH receptor agonism on somatotroph cells and the downstream signalling cascade this triggers, using tesamorelin as a tool compound because its resistance to DPP-4 cleavage produces a more stable exposure profile than native GRF(1-44) in experimental preparations.
Because tesamorelin preserves the full 44-residue sequence, it also appears in study designs that compare full-length GHRH structure-activity relationships against those of truncated 29-residue fragments, examining whether the additional sequence contributes to receptor binding characteristics beyond what the minimal active fragment provides. Some literature further examines GHRH analogues alongside growth hormone secretagogue receptor ligands, since the two act on distinct receptor pathways within the same axis and the combination is used to probe pathway interaction in model systems.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent you add to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What distinguishes tesamorelin from other GHRH analogue peptides?
Tesamorelin retains the complete 44-residue GRF sequence, whereas several other synthetic GHRH analogues use a truncated 29-residue fragment. Its N-terminal hexenoyl modification is reported to confer resistance to DPP-4 cleavage without the albumin-binding domain used in some longer-acting DAC-conjugated compounds.
Is TESAMORELIN approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.